Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;18(11):E339-E345.
doi: 10.5489/cuaj.8774.

Medical treatment of uric acid kidney stones

Affiliations

Medical treatment of uric acid kidney stones

Michel Normand et al. Can Urol Assoc J. 2024 Nov.

Abstract

Introduction: The prevalence of uric acid (UA) stones increases regularly due to its high correlation with obesity, hypertension, metabolic syndrome, type 2 diabetes, and aging. Uric acid stone formation is mainly due to an acidic urinary pH secondary to an impaired urinary ammonium availability responsible for UA rather than soluble urate excretion. Alkalization of urine is therefore advocated to prevent UA crystallization and considered effective therapy.

Methods: We report a large series of 120 patients with UA lithiasis who were successfully treated with potassium (K)-citrate for stone dissolution (n=75) and/or stone recurrence prevention (n=45) without any urologic intervention, with a median 3.14 years followup. The K-citrate was diluted in 1.5 L of water, avoiding gastrointestinal disorders.

Results: Among 75 patients having stones in their kidney at initiation of therapy, a complete chemolysis was obtained in 88% of cases. Stone risk factors decreased under treatment, mainly due to increased diuresis, urinary pH, and citrate excretion. Treatment was stopped in only 2% of patients due to side effects, with no hyperkalemia onset despite a median urinary potassium increase of 44 mmol/day.

Conclusions: Contrary to other reports, our data show that medical treatment of UA kidney stones is well-tolerated and efficient if regular monitoring of urinary pH is performed.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Computed tomography scans of two patients’ before (left) and after 3 months of K-citrate treatment (right) showing the dissolution of calculi.

References

    1. Daudon M. Épidémiologie actuelle de la lithiase rénale en France. Ann Urol. 2005;39:209–31. doi: 10.1016/j.anuro.2005.09.007. - DOI - PubMed
    1. Sakhaee K, Maalouf NM. Kidney stones 2012: Pathogenesis, diagnosis and management. J Clin Endocrin Metab. 2012;97:1847–60. doi: 10.1210/jc.2011-3492. - DOI - PMC - PubMed
    1. Daudon M, Jungers P, Bazin D, et al. Recurrence rates of urinary calculi according to stone composition and morphology. Urolithiasis. 2018;46:459–70. doi: 10.1007/s00240-018-1043-0. - DOI - PMC - PubMed
    1. Straub M, Hautmann RE. Developments in stone prevention. Curr Opin Urol. 2005;15:119–26. doi: 10.1097/01.mou.0000160627.36236.6b. - DOI - PubMed
    1. Trinchieri A, Esposito N, Castelnuovo C. Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate. Arch Ital Androl. 2009;81:188–91. - PubMed

LinkOut - more resources